<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="17579" end="17583" sStart="17269" offset="310" sid="r11.true.j.0767" wn="5" wnkey="true%5:00:00:typical:00" text="The summary statistic is a weighted average of the estimated effect of receipt of treatment for each hospital or medical center, where the weight for each hospital or medical center is the reciprocal of the sum of the sampling variance and the variance of the true effect over the studies." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="17967" end="17971" sStart="null" offset="23" sid="r11.true.j.0282" wn="5" wnkey="true%5:00:00:typical:00" text="The variability of the true effect, which arises because the medical intervention is not exactly identical among all hospitals, is computed using the formula in DerSimonian and Laird [ 19 ] . The standard error of the summary statistic is the square root of the reciprocal of the sum of the weights." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2288-1-9.anc" start="16234" end="16241" sStart="null" offset="0" sid="null" wn="1" wnkey="succeed%2:41:00::" text="If the outcome measure is binary, such as &lt;b&gt;success&lt;/b&gt; or failure, D is a difference in the fraction who fail or &lt;b&gt;succeed&lt;/b&gt; in the &quot;before&quot; and &quot;after&quot; groups." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2288-1-9.anc" start="16234" end="16241" sStart="null" offset="0" sid="null" wn="1" wnkey="succeed%2:41:00::" text="If the outcome measure is binary, such as &lt;b&gt;success&lt;/b&gt; or failure, D is a difference in the fraction who fail or &lt;b&gt;succeed&lt;/b&gt; in the &quot;before&quot; and &quot;after&quot; groups." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="6361" end="6370" sStart="null" offset="13" sid="r11.recommend.v.0413" wn="1" wnkey="recommend%2:32:01::" text="We recommend limiting the total study duration to not more than two years, recognizing there may be exceptions due to patient accrual rate, intervention, and outcome." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="25728" end="25737" sStart="null" offset="75" sid="r11.recommend.v.0099" wn="2" wnkey="recommend%2:32:00::" text="If the requirements for the paired availability design are met, we recommend it as an alternative with advantages over the usual analyses from observational studies." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="15117" end="15126" sStart="null" offset="53" sid="r11.recommend.v.0414" wn="1" wnkey="recommend%2:32:01::" text="In such situations, as a rule of thumb, we recommend a minimum of 10 hospitals or medical centers, with 15 preferable, and 20 ideal." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="25728" end="25737" sStart="null" offset="75" sid="r11.recommend.v.0099" wn="2" wnkey="recommend%2:32:00::" text="If the requirements for the paired availability design are met, we recommend it as an alternative with advantages over the usual analyses from observational studies." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="20270" end="20280" sStart="null" offset="116" sid="r10.particular.j.0082" wn="2147483647" wnkey="null" text="A slightly simplified version of the data from Baker and Lindeman [ 9 ] is given in Table 3. In particular, to simplify the calculations for the hospital designated as number 11, we regrouped data from multiple time periods into two time periods." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="20270" end="20280" sStart="null" offset="116" sid="r10.particular.j.0082" wn="2147483647" wnkey="null" text="A slightly simplified version of the data from Baker and Lindeman [ 9 ] is given in Table 3. In particular, to simplify the calculations for the hospital designated as number 11, we regrouped data from multiple time periods into two time periods." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="20270" end="20280" sStart="null" offset="116" sid="r10.particular.j.0082" wn="2147483647" wnkey="null" text="A slightly simplified version of the data from Baker and Lindeman [ 9 ] is given in Table 3. In particular, to simplify the calculations for the hospital designated as number 11, we regrouped data from multiple time periods into two time periods." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="20270" end="20280" sStart="null" offset="116" sid="r10.particular.j.0082" wn="3" wnkey="particular%5:00:00:uncommon:00" text="A slightly simplified version of the data from Baker and Lindeman [ 9 ] is given in Table 3. In particular, to simplify the calculations for the hospital designated as number 11, we regrouped data from multiple time periods into two time periods." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="21148" end="21152" sStart="null" offset="32" sid="r10.high.j.0991" wn="1" wnkey="high%3:00:02::" text="02, .08) [ 9 ] . In contrast, a high quality propensity score analysis of cohort data gave a much larger estimate of." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="575" end="581" sStart="null" offset="4" sid="r10.common.j.0244" wn="4" wnkey="common%5:00:00:familiar:02" text="One common method of inference from observational data is the cohort study with an adjustment for risk factors using, for example, regression models [ 1 ] and propensity scores [ 2 ] . In some situations, estimates from high-quality cohort studies have been similar to those from randomized trials [ 2 ] [ 3 ] [ 4 ] [ 5 ] . However there are some notable exceptions, including studies of the effect of beta-carotene on cardiovascular mortality [ 6 ] [ 7 ] , the effect of hormone therapy on the rate of cardiovascular disease [ 8 ] , the effect of epidural analgesia on the probability of Cesarean section [ 9 ] , the effect of beta-blockers on mortality [ 10 ] , and the effect of aspirin on the risk of colorectal cancer [ 11 ] . Some of the discrepancy between the results of these high quality cohort studies and randomized trials may be explained by differences in the intervention, patient population, or duration of follow-up." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="6005" end="6011" sStart="null" offset="67" sid="r9.appear.v.0379" wn="4" wnkey="appear%2:39:01::" text="Although implementing a multi-center study may initially appear burdensome, two mitigating factors lessen the burden: (1) randomization is not required and (2) investigators need not collect data on risk factors if the requirements hold." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2288-1-9.anc" start="11435" end="11442" sStart="null" offset="76" sid="r11.absence.n.0362" wn="1" wnkey="absence%1:26:00::" text="The fourth requirement, stable preference, is strengthened in the absence of new information in the &quot;after&quot; period that would change a subject's preference for the medical intervention." />
  </sentences>
</list>